DELIVERING VALUE INOVIQ’s vision is to be a leading biotechnology company delivering next-generation cancer diagnostics and therapeutics to enhance patient outcomes in cancer and other diseases. The Company has proprietary technologies, in-market products and a strong development pipeline of cancer diagnostics and therapeutics. INOVIQ is developing best-in-class diagnostics and therapeutics for global markets that deliver value to patients, clinicians, the health system and investors. The Company has three key business pillars built around our disruptive technologies that underpin its short and longer-term product development and revenue generating opportunities: 1. Research tools: The EXO-NET technology is a source of current and future revenue streams including EXO-NET pan-exosome sold for research purposes, custom EXO-NET products and exosome services to develop exosome-based diagnostics for contract research fees and potential future licensing revenue; 2. Diagnostics: The diagnostic pipeline includes both internal and partnered diagnostic tests developed using our SubB2M and EXO-NET technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases; and 3. Therapeutics: The longer-term focus is on developing high-value exosome therapeutics to target and kill cancer, enabled by our EXO-ACE technology for therapeutic exosome isolation and production. INOVIQ is growing shareholder value through commercialisation of the Company’s lead SubB2M cancer diagnostics, developing a multi-product exosome pipeline, diversifying risk across multiple applications and building a revenue generating business. The Company’s strategic focus and business pillars supporting our current pipeline and future growth are depicted below: STRATEGIC FOCUS Next-generation exosome diagnostics and therapeutics for cancer RESEARCH TOOLS DIAGNOSTICS THERAPEUTICS Exosome therapeutics to target and kill solid tumours CORE TECHNOLOGIES BUSINESS SEGMENTS Exosome Platform NETs™ immunoaffinity, magnetic bead-based EV isolation EXO-ACE™ affinity chromatography large-scale EV isolation SubB2M Technology Proprietary neu5Gc probe for improved cancer detection 6 INOVIQ Limited Review of Operations continued EXO-NET® exosome isolation tools for biomarker discovery and diagnostics development Exosome tests for screening, liquid biopsies & companion diagnostics SubB2M tests for cancer detection & monitoring US$661m US$6.1b US$55.3b
RkJQdWJsaXNoZXIy MjE2NDg3